Plasma from patients with HELLP syndrome increases blood-brain barrier permeability

Reproductive Sciences

Volumn 22, Issue 3, 2015, Pages 278-284

  Wallace, Kedra ^a   Tremble, Sarah M ^b   Owens, Michelle Y ^a   Morris, Rachael ^a   Cipolla, Marilyn J ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

blood brain barrier permeability; HELLP syndrome; myogenic response

Indexed keywords

INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; NS 309; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NITRIC OXIDE SYNTHASE; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADULT; ANIMAL EXPERIMENT; ARTERY LIGATION; ARTICLE; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER PERMEABILITY; BLOOD SAMPLING; BLOOD VESSEL; BLOOD VESSEL REACTIVITY; BRAIN ARTERY; CONTROLLED STUDY; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; FEMALE; HEADACHE; HELLP SYNDROME; HUMAN; HYDRAULIC CONDUCTIVITY; NEUROLOGICAL COMPLICATION; NONHUMAN; POSTERIOR CEREBRAL ARTERY; PREGNANCY; PRIORITY JOURNAL; RAT; TONIC CLONIC SEIZURE; ADOLESCENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CAPILLARY PERMEABILITY; CASE CONTROL STUDY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME FACTOR; VASOCONSTRICTION; VASODILATATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HELLP SYNDROME; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; POSTERIOR CEREBRAL ARTERY; PREGNANCY; RATS, SPRAGUE-DAWLEY; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84924812458     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114549844     Document Type: Article

References (20)

1. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth. 2009; 9: 8
2. Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol. 2013; 166: 117-123
3. Vigil-de Gracia P, Tenorio-Maranon F, Cejudo-Carranza E, Helquera-Martinez A, Garcia-Caceres E. Difference between preeclampsia, HELLP syndrome and eclampsia, maternal evaluation. Ginecol Obstet Mex. 1996; 64: 377-382
4. Habli M, Eftekhari N, Wiebracht E, et al. Long-term maternal and subsequent pregnancy outcomes 5 years after hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Am J Obstet Gynecol. 2009; 201 (4). e1-e5
5. Altamura C, Vasapollo B, Tibuzzi F, et al. Postpartum cerebellar infarction and haemolysis, elevated liver enzymes, low platelet (HELLP) syndrome. Neurol Sci. 2005; 26 ((1)). 40-42
6. Cipolla M. Cerebrovascular function in pregnancy and eclampsia. Hypertension. 2007; 50 ((1)). 14-24
7. Euser A, Cipolla M. Cerebral blood flow autoregulation and edema formation during pregnancy in anesthetized rats. Hypertension. 2007; 49 ((2)). 334-340
8. Foyouzi N, Norwitz E, Tsen L, Buhimschi C, Buhimschi I. Placental growth factor in the cerebrospinal fluid of women with preeclampsia. Int J Gynaecol Obstet. 2006; 92 ((1)). 32-37
9. Schreurs M, Houston E, May V, Cipolla M. The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy. FASEB J. 2012; 26 ((1)). 355-362
10. Amburgey O, Chapman A, May V, Bernstein I, Cipolla M. Plasma from preeclamptic women increases blood-brain barrier permeability. Hypertension. 2010; 56 ((5)). 1003-1008
11. Wallace K, Martin J, Tam Tam K, et al. Seeking the mechanisms of action for corticosteroids in HELLP syndrome: SMASH study. Am J Obstet Gynecol. 2013; 208 ((5)). e1-e8
12. Diagnosis and Management of Preeclampsia and Eclampsia. Washington, DC: ACOG; 2002 :
13. Roberts T, Chapman A, Cipolla M. PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension. Am J Physiol Heart Circ Physiol. 2009; 297: H1347-H1353
14. Schreurs M, Cipolla M. Cerebrovascular dysfunction and blood-brain barrier permeability induced by oxidized LDL are prevented by apocynin and magnesium sulfate in female rats. J Cardiovasc Pharmacol. 2014; 63 ((1)). 33-39
15. Hinton J, Langton P. Inhibition of EHDF by two new combinations of K+-channel inhibitors in rat isolated arteries. Br J Pharmacol. 2003; 138 ((6)). 1031-1035
16. Hannah R, Dunn K, Bonev A, Nelson M. Endothelial SKCA and IKCA channels regulate brain parenchymal arteriolar diameter and cortical cerebral blood flow. J Cereb Blood Flow Metab. 2011; 31 ((5)). 1175-1186
17. Sonkusare S, Bonev A, Ledoux J, et al. Elementary Ca2+ signals through endothelial TRPV4 channels regulate vascular function. Science. 2012; 336 ((6081)). 597-601
18. Takata F, Dohgu S, Yamauchi A, et al. In vitro blood-brain barrier models using brain capillary endothelial cells isolated from neonatal and adult rats retain age-related barrier properties. PLoS One. 2013; 8 (1). e55166
19. Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009; 54 ((3-4)). 253-263
20. Saraf S, Egbert NM, Mittal G, Homel P, Minkoff H, Fisher N. Predictors of posterior reversible encephalopathy syndrome in preeclampsia and eclampsia. Obstet Gynecol. 2014; 123 (S1). 169S